MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the equity
line of credit
$3,602K
Proceeds from the sale and
exercise of prefunded...
$3,058K
Net cash provided by
financing activities
$6,660K
Net increase in cash
and cash...
$3,219K
Canceled cashflow
$3,441K
Amortization of vendor
advances
$2,170K
Fair value of vested
restricted stock units
$482K
Amortization of intangible
asset
$160K
Net increase in cash
and cash...
$3,219K
Net cash used in
operating activities
-$3,441K
Canceled cashflow
$2,812K
Net loss
-$5,447K
Accounts payable and
accrued expenses
-$793K
Prepaid expenses and
other current assets
$13K
Back
Back
Cash Flow
source: myfinsight.com
Kairos Pharma, LTD. (KAPA)
Kairos Pharma, LTD. (KAPA)